Gilead Sciences: Underestimated Biotech Giant with Surprising Growth Potential
ByAinvest
Friday, Feb 6, 2026 9:02 pm ET1min read
GILD--
Gilead Sciences' Q4 earnings are expected to show significant momentum in its HIV franchise, with total revenue rising 3% YoY to $7.8 billion. The company's HIV product sales grew 4% YoY to $5.3 billion, driven by strong demand for Biktarvy and Descovy. The PrEP market expanded at a rate of 14%-15% YoY, expected to sustain through 2026. The liver disease portfolio also had a strong quarter, with sales up 12% YoY to $819 million.
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet